ReviewCancers2024
Mesothelioma of the Tunica Vaginalis Testis: Diagnostic and Therapeutic Management. A Comprehensive Review, 1982-2024.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Malignant mesothelioma of the tunica vaginalis testis: A case report.Oncology letters · 2026Article
- Primary malignant mesothelioma of the tunica vaginalis presenting as hydrocele: imaging pitfalls.BMJ case reports · 2026Article
- Mesothelioma of the Tunica Vaginalis Testis Initially Treated as Hydrocele: A Case Report.IJU case reports · 2026Article
- Article
- Efficacy of Nivolumab in Chemotherapy-Resistant Mesothelioma of the Tunica Vaginalis Testis: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- When a hydrocele is more than a hydrocele: Warning symptoms and signs of malignant mesothelioma of the tunica vaginalis testis.Urology case reports · 2026Article
- Malignant mesothelioma of the tunica vaginalis: A case report and comprehensive literature review.Urology case reports · 2026Article
- Malignant mesothelioma of the tunica vaginalis testis initially misdiagnosed as a benign testicular hydrocele: a case report.Frontiers in oncology · 2026Article
- Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma.Annals of surgical oncology · 2025Article
- Diagnostic and Therapeutic Management of Mesothelioma of the Tunica Vaginalis Testis: A Population-Based Study in Italy.Cancers · 2025Article
- Primary Malignant Mesothelioma of the Tunica Vaginalis: A Case Report and Review of the Literature.Cureus · 2025Article
- Article
- Primary Malignant Mesothelioma of the Tunica Vaginalis Presenting as a Benign Scrotal Mass: A Case Report.Cureus · 2025Article
- Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives.Oncology research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMesothelioma of the tunica vaginalis testis (MTVT) is an extremely rare and aggressive cancer. The diagnosis and management of MTVT is complex, and no standard treatment protocol is available.
methodsWe conducted a systematic literature review from 1 January 1982 to 14 March 2024 using PubMed to collect all the available case reports and case series. A descriptive analysis of patient characteristics with clinical presentation, diagnostic work-up, therapeutic management, and past asbestos exposure was performed. Survival times of patients treated with different therapeutic approaches were evaluated.
resultsOverall, 289 patients with MTVT were included in our analysis. The most common clinical presentations were scrotal/testicular swelling or mass (187 patients, 65%) and the presence of hydrocele (159, 55%). Imaging evaluation, mostly with ultrasonography or CT scan, was reported in two-thirds of cases. Radical surgery (216 patients, 75%) with orchiectomy and, in select cases, hemiscrotectomy and inguinal lymphadenectomy was the most frequent therapeutic approach. A minority of patients (49, 17%) received adjuvant therapy after surgery (radiotherapy, chemotherapy, or a combination of the two), with no evidence of survival improvement.
conclusionsNo standard guidelines for MTVT are available so far. Radical surgery following accurate radiological staging should be the mainstay of treatment. The role of adjuvant treatments remains undefined. Due to its rarity, MTVT should be treated in referral centers, and patients' data should be collected in a dedicated register in order to improve the knowledge of this exceedingly rare disease and establish optimal diagnostic and therapeutic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.